Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Open accessThe DOI matches its Crossref record; 94 of the 95 references it cites were found in a registry or an index.
Abstract
Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections. Chemotherapy-induced diarrhea (CID) is a common problem, especially in patients with advanced cancer. The incidence of CID has been reported to be as high as 50-80% of treated patients (≥30% CTC grade 3-5), especially with 5-fluorouracil bolus or some combination therapies of irinotecan and fluoropyrimidines (IFL, XELIRI). Regardless of the molecular targeted approach of tyrosine kinase inhibitors and antibodies, diarrhea is a common side effect in up to 60% of patients with up to 10% having severe diarrhea. Furthermore, the underlying pathophysiology is still under investigation. Despite the number of clinical trials evaluating therapeutic or prophylactic measures in CID, there are just three drugs recommended in current guidelines: loperamide, deodorized tincture of opium and octreotide. Newer strategies and more effective agents are being developed to reduce the morbidity and mortality associated with CID. Recent research focusing on the prophylactic use of antibiotics, budesonide, probiotics or activated charcoal still have to define the role of these drugs in the routine clinical setting. Whereas therapeutic management and clinical work-up of patients presenting with diarrhea after chemotherapy are rather well defined, prediction and prevention of CID is an evolving field. Current research focuses on establishing predictive factors for CID like uridine diphosphate glucuronosyltransferase-1A1 polymorphisms for irinotecan or dihydropyrimidine-dehydrogenase insufficiency for fluoropyrimidines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The resulting SN-38 in the gut lumen exhibits toxicity towards intestinal epithelial cells and is thought to exacerbate the diarrhea found in up to 80% of CRC patients50, 51.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“Irinotecan is frequently used in first- and second-line treatment of metastatic colorectal cancer [Saltz et al. 2000, 2007; Hurwitz et al. 2004; Jordan et al. 2004; Van Cutsem et al. 2009].”
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115 · cited 1×
“However, there was no increase in toxicity of head and neck radiation by addition of cetuximab in a phase III trial despite a possible correlation between EGFR targeting and maturation of squamous eptithelium of the tongue and nasal cavity [Bonner et al. 2006; Keefe and Gibson, 2007].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“For monoclonal antibodies (mAb), such as the chimeric IgG1 mAb cetuximab or the fully human IgG2 mAb panitumumab, rates of grade 2 diarrhea are up to 21% and for grade 3 (ie greater than 7 stools per day or requiring intravenous fluids) between 1 and 2% [Van Cutsem et al. 2007; Davila and Bresalier, 2008; Vincenzi et…”
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647 · cited 2×
“…Everolimus and temsirolimus (inhibitors of the mammalian target of rapamycin [m-TOR]) were both recently approved for treatment of renal cell cancer, causing diarrhea in up to 40% with a rate of severe diarrhea in less than 5% of patients [Hudes et al. 2007; Motzer et al. 2008; Hess et al. 2009].”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“…Everolimus and temsirolimus (inhibitors of the mammalian target of rapamycin [m-TOR]) were both recently approved for treatment of renal cell cancer, causing diarrhea in up to 40% with a rate of severe diarrhea in less than 5% of patients [Hudes et al. 2007; Motzer et al. 2008; Hess et al. 2009].”
BackgroundIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005 · cited 2×
“Irinotecan is frequently used in first- and second-line treatment of metastatic colorectal cancer [Saltz et al. 2000, 2007; Hurwitz et al. 2004; Jordan et al. 2004; Van Cutsem et al. 2009].”
BackgroundMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181 · cited 1×
“Multitargeting tyrosine kinase inhibitors Sorafenib and sunitinib cause diarrhea in 30 50% of patients (all grades) with a rate of less than 10% of grade 3 diarrhea [Llovet et al. http://tam.sagepub.com 55 2008; Gore et al. 2009; Motzer et al. 2009].”
BackgroundVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 1×
“…such as the chimeric IgG1 mAb cetuximab or the fully human IgG2 mAb panitumumab, rates of grade 2 diarrhea are up to 21% and for grade 3 (ie greater than 7 stools per day or requiring intravenous fluids) between 1 and 2% [Van Cutsem et al. 2007; Davila and Bresalier, 2008; Vincenzi et al. 2008].”
BackgroundTargeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179 · cited 1×
“Increased levels of EGFR are found in inflamed mucosa, particulary in goblet cells, which seem to play a role in CID [Threadgill et al. 1995].”
BackgroundInnocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964 · cited 1×
“[Iyer et al. 2002; Innocenti et al. 2004].”
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720 · cited 1×
“[Iyer et al. 2002; Innocenti et al. 2004].”
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641 · cited 2×
“…Everolimus and temsirolimus (inhibitors of the mammalian target of rapamycin [m-TOR]) were both recently approved for treatment of renal cell cancer, causing diarrhea in up to 40% with a rate of severe diarrhea in less than 5% of patients [Hudes et al. 2007; Motzer et al. 2008; Hess et al. 2009].”
BackgroundRecommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.132 · Cited by 631 · cited 8×
“The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization [Benson et al. 2004; Maroun et al. 2007].”
BackgroundMethodInfluentialSafety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Hariharan, S., Lee, S.-H., Haanen, J., Castellano, D., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70162-7 · Cited by 589 · cited 1×
“Multitargeting tyrosine kinase inhibitors Sorafenib and sunitinib cause diarrhea in 30 50% of patients (all grades) with a rate of less than 10% of grade 3 diarrhea [Llovet et al. http://tam.sagepub.com 55 2008; Gore et al. 2009; Motzer et al. 2009].”
BackgroundUGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469 · cited 1×
“[Hoskins et al. 2007; Kim et al. 2007].”
Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L. A., & Mayer, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2144 · Cited by 449 · cited 1×
“Irinotecan is frequently used in first- and second-line treatment of metastatic colorectal cancer [Saltz et al. 2000, 2007; Hurwitz et al. 2004; Jordan et al. 2004; Van Cutsem et al. 2009].”
Österlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., Kouri, M., Elomaa, I., & Joensuu, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603990 · Cited by 405 · cited 2×
“…gliomas treated with irinotecan and celecoxib [Reardon et al. 2005], whereas in another study with the same sample size using a combination of celecoxib and glutamine with the IFL-regimen the rate was 45% for grade 3 diarrhea, which is even higher than the expected margin [Pan et al. 2005].”
ResultPractical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402 · cited 1×
“The high expression of Kit in the interstitial cells of Cajal, which function as pacemaker cells of the intestinal motility, might be a potential mechanism for diarrhea induced by imatinib or sunitinib [Deininger et al. 2003].”
BackgroundKeefe, D. M. K. (2000) · Gut · doi:10.1136/gut.47.5.632 · Cited by 368 · cited 2×
“CID appears to be a multifactorial process whereby acute damage to the intestinal mucosa (including loss of intestinal epithelium, superficial necrosis and inflammation of the bowel wall) causes an imbalance between absorption and secretion in the small bowel [Keefe et al. 2000; Keefe, 2007; Gibson and Stringer, 2009].”
BackgroundIrinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344 · cited 2×
“A review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitorin…”
BackgroundEffect of a Glutamine‐Supplemented Enteral Diet on Methotrexate‐Induced Enterocolitis
Fox, A. D., Kripke, S. A., De Paula, J., Berman, J. M., Settle, R. G., & Rombeau, J. L. (1988) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607188012004325 · Cited by 317 · cited 1×
“Preclinical data suggests that glutamine stimulates intestinal mucosa growth, displaying less gastrointestinal toxictiy in rodents treated with chemotherapy [Fox et al. 1988; Xue et al. 2008].”
BackgroundMeyerhardt, J. A., Tepper, J. E., Niedzwiecki, D., Hollis, D. R., McCollum, A. D., Brady, D., O'Connell, M. J., Mayer, R. J., Cummings, B., Willett, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.121 · Cited by 273 · cited 1×
“The discontinuation rate of irinotecan was much lower and less loperamide was used [Michael et al. 2004; Sergio et al. 2008].”
MethodComprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262 · cited 2×
“SN-38 in the active form into the blood and in the glucuronidated form into the bile (Figure 1) [De Jong et al. 2007; Han et al. 2009; Innocenti et al. 2009].”
BackgroundSevere CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., & Cvitkovic, E. (1997) · Annals of Oncology · doi:10.1023/a:1008261821434 · Cited by 213 · cited 2×
“UGT1A1 was one of the first factors to be investigated, due to the observation of severe toxicities in patients with inherited disorders characterized by decreased bilirubin glucuronidation like Gilbert’s syndrome (i.e. mild unconjugated hyperbilirubinemia) [Wasserman et al. 1997a].”
BackgroundVSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss
Bowen, J. M., Stringer, A. M., Gibson, R. J., Yeoh, A. S., Hannam, S., & Keefe, D. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4622 · Cited by 202 · cited 1×
“Preclinical data yielded a similar efficacy in CID [Von Bultzingslowen et al. 2003; Bowen et al. 2007].”
ResultTrifan, O. C., Durham, W. F., Salazar, V. S., Horton, J., Levine, B. D., Zweifel, B. S., Davis, T. W., & Masferrer, J. L. (2002) · PubMed · Cited by 195
Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S., & Keefe, D. M. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.6940 · Cited by 194 · cited 2×
“In feces, SN38 was found to be in excess relative to SN38G, which is suggestive of substantial ß-glucuronidase activity in the human intestinal contents [Saliba et al. 1998; Stringer et al. 2008].”
BackgroundGIBSON, R. J., BOWEN, J. M., INGLIS, M. R., CUMMINS, A. G., & KEEFE, D. M. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03136.x · Cited by 183 · cited 1×
“Increased levels of cell apoptosis combined with the histopathological changes in both the jejunum and colon and the changes in goblet cell numbers may cause changes in absorption rates, possibly leading to diarrhea [Gibson et al. 2003].”
BackgroundModulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Kehrer, D. F. S., Sparreboom, A., Verweij, J., de Bruijn, P., Nierop, C. A., van de Schraaf, J., Ruijgrok, E. J., & de Jonge, M. J. (2001) · PubMed · Cited by 176
Mattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0747 · Cited by 174 · cited 2×
“Potentially, the simple breath test (UraBT) could be used as a screening tool [Mattison et al. 2006b].”
BackgroundMethodIrinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
de Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H., Verweij, J., Marsh, S., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100019 · Cited by 171 · cited 1×
“…and genetic variations of SLCO1B1 and ABC-transporters were investigated, with the latter playing a pivotal role in the excretion of SN-38 in the active form into the blood and in the glucuronidated form into the bile (Figure 1) [De Jong et al. 2007; Han et al. 2009; Innocenti et al. 2009].”
BackgroundDuPont, H. L. (1997) · PubMed · Cited by 164
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler, S., Benson, A. B., Engelking, C., Catalano, R., Field, M., Kornblau, S. M., Mitchell, E., Rubin, J., Trotta, P., & Vokes, E. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3169 · Cited by 164 · cited 1×
“Guidelines for evaluation and management of patients with CID are presented in Figure 2 [Wadler et al. 1998, Benson et al. 2004].”
MethodMaroun, J. A., Anthony, L. B., Blais, N., Burkes, R., Dowden, S. D., Dranitsaris, G., Samson, B., Shah, A., Thirlwell, M. P., Vincent, M. D., et al. (2007) · Current Oncology · doi:10.3747/co.2007.96 · Cited by 161 · cited 2×
“…as metabolic acidosis and depending upon water intake, hyponatremia (increased water intake that cannot be excreted because of the hypovolemic stimulus to the release of antidiuretic hormone) or hypernatremia (insufficient water intake to replace losses) [Benson et al. 2004; Maroun et al. 2007].”
BackgroundMcCollum, A. D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.15.1160 · Cited by 146 · cited 1×
“Clinical factors predictive for fluoropyrimidine-induced diarrhea are female sex, caucasian race and presence of diabetes [Zalcberg et al. 1998; McCollum et al. 2002; Meyerhardt et al. 2004].”
BackgroundSaliba, F., Hagipantelli, R., Misset, J. L., Bastian, G., Vassal, G., Bonnay, M., Herait, P., Cote, C., Mahjoubi, M., Mignard, D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2745 · Cited by 144 · cited 2×
“contents [Saliba et al. 1998; Stringer et al. 2008].”
BackgroundRichardson, G., & Dobish, R. (2007) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155207077335 · Cited by 135
Daniele, B., Perrone, F., Gallo, C., Pignata, S., Martino, S. D., Vivo, R. D., Barletta, E., Tambaro, R., Abbiati, R., & D'Agostino, L. (2001) · Gut · doi:10.1136/gut.48.1.28 · Cited by 132 · cited 2×
“Results from randomized studies showed a nonsignificant reduction in the CID rate [Daniele et al. 2001], and no effect in the prevention of radiation-induced diarrhea for the oral application form of glutamine was revealed [Kozelsky et al.”
ResultShould DPD analysis be required prior to prescribing fluoropyrimidines?
Yen, J. L., & McLeod, H. L. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.030 · Cited by 124 · cited 1×
“The current genotyping strategies are not yet available for routine use [Yen and McLeod, 2007].”
MethodLiu, C., Chen, P., Chiou, T.-J., Liu, H., Lin, J., Lin, T., Chen, W., Jiang, J., Wang, H., & Wang, W.-S. (2008) · Cancer · doi:10.1002/cncr.23370 · Cited by 122 · cited 1×
“In a retrospective analysis of the Dutch CAIRO trial, a reduced performance status and not the UGT1A1*28 genotype was a predictor for febrile neutropenia in a bivariate analysis [Kweekel et al. 2008; Liu et al. 2008].”
Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050818 · Cited by 120 · cited 2×
“(3) The distribution and severity of histological damage within the rat intestine after administration of irinotecan has been correlated to the luminal ß-glucuronidase activity in rodents [Takasuna et al. 1998; Fittkau et al. 2004].”
BackgroundPhase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Badruddoja, M., Herndon, J. E., Dowell, J. M., Friedman, A. H., & Friedman, H. S. (2004) · Cancer · doi:10.1002/cncr.20776 · Cited by 117 · cited 2×
“The rate of grade 3 diarrhea was only 8% in one trial of 43 patients suffering from malignant gliomas treated with irinotecan and celecoxib [Reardon et al. 2005], whereas in another study with the same sample size using a combination of celecoxib and glutamine with the IFL-regimen the rate was 45% for grade 3 diarrhea…”
BackgroundResultZalcberg, J. R., Kerr, D. J., Seymour, L. W., & Palmer, M. K. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00259-7 · Cited by 115 · cited 1×
“Clinical factors predictive for fluoropyrimidine-induced diarrhea are female sex, caucasian race and presence of diabetes [Zalcberg et al. 1998; McCollum et al. 2002; Meyerhardt et al. 2004].”
BackgroundBültzingslöwen, I. V., Adlerberth, I., Wold, A. E., Dahlén, G., & Jontell, M. (2003) · Oral Microbiology and Immunology · doi:10.1034/j.1399-302x.2003.00075.x · Cited by 112 · cited 1×
“Preclinical data yielded a similar efficacy in CID [Von Bultzingslowen et al. 2003; Bowen et al. 2007].”
ResultPytlík, R., Beneš, P., Pat'orková, M., Chocenská, E., Gregora, E., Procházka, B., & Kozák, T. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703759 · Cited by 108 · cited 2×
“Importantly, a trial in patients receiving high-dose chemotherapy and glutamine-containing intravenous 56 http://tam.sagepub.com solutions showed significantly more relapses and deaths in the glutamine group [Pytlik et al. 2002].”
BackgroundHan, J., Lim, H., Park, Y. H., Lee, S., & Lee, J. S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.003 · Cited by 107 · cited 2×
“SN-38 in the active form into the blood and in the glucuronidated form into the bile (Figure 1) [De Jong et al. 2007; Han et al. 2009; Innocenti et al. 2009].”
BackgroundKozelsky, T. F., Meyers, G. E., Sloan, J. A., Shanahan, T. G., Dick, S. J., Moore, R. L., Engeler, G. P., Frank, A. R., McKone, T. K., Urias, R. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.060 · Cited by 102 · cited 2×
“2001], and no effect in the prevention of radiation-induced diarrhea for the oral application form of glutamine was revealed [Kozelsky et al. 2003].”
BackgroundResultChemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.
Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., Burns, J., & Keefe, D. M. K. (2007) · PubMed · Cited by 102
Keefe, D. M. K., Gibson, R. J., & Hauer‐Jensen, M. (2004) · Seminars in Oncology Nursing · doi:10.1053/j.soncn.2003.10.007 · Cited by 101 · cited 1×
“Therapeutic agents commonly causing diarrhea include 5-fluorouracil (5-FU), capecitabine and irinotecan (CPT-11) [Benson et al. 2004; Keefe et al. 2004].”
BackgroundArbuckle, R. B., Huber, S. L., & Zacker, C. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-250 · Cited by 100 · cited 2×
“A review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitorin…”
BackgroundIrinotecan-induced mucositis is associated with changes in intestinal mucins
Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., Laurence, J., & Keefe, D. M. K. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0855-y · Cited by 94 · cited 1×
“Therefore the increase of mucin secretion is likely to be related to altered mucine gene expression, and may contribute to diarrhea induced by irinotecan [Stringer et al. 2009].”
BackgroundIntestinal mucositis: mechanisms and management
Keefe, D. M. K. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3281214412 · Cited by 90 · cited 2×
“CID appears to be a multifactorial process whereby acute damage to the intestinal mucosa (including loss of intestinal epithelium, superficial necrosis and inflammation of the bowel wall) causes an imbalance between absorption and secretion in the small bowel [Keefe et al. 2000; Keefe, 2007; Gibson and Stringer, 2009].”
Backgroundde Jong, F. A., Kehrer, D. F. S., Mathijssen, R. H. J., Creemers, G., de Bruijn, P., van Schaik, R. H. N., Planting, A. S. T., van der Gaast, A., Eskens, F. A. L. M., Janssen, J., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-8-944 · Cited by 89 · cited 1×
“Despite promising results in a small series for secondary prophylaxis [Schmittel et al. 2004], a recent randomized phase II study displayed only a nonsignificant reduction of grade 3 diarrhea from 32.4 to 17.9% [De Jong et al. 2006].”
ResultInfluentialKweekel, D. M., Gelderblom, H. A. J., van der Straaten, T., Antonini, N. F., Punt, C. J. A., & Guchelaar, H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604461 · Cited by 87 · cited 1×
“In a retrospective analysis of the Dutch CAIRO trial, a reduced performance status and not the UGT1A1*28 genotype was a predictor for febrile neutropenia in a bivariate analysis [Kweekel et al. 2008; Liu et al. 2008].”
MethodOctreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
Cascinu, S., Fedeli, A., Fedeli, S. L., & Catalano, G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.148 · Cited by 85 · cited 2×
“…in 41 5-FU-treated patients showed that octreotide was more effective than standard-dose loperamide (90 versus 15% resolution of diarrhea by day 3) [Cascinu et al. 1993], octreotide is generally reserved as a second-line treatment for patients who are refractory after 48 hours, despite a…”
BackgroundPhase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea
Michael, M., Brittain, M.-A., Nagai, J., Feld, R. D., Hedley, D. W., Oza, A. M., Siu, L. L., & Moore, M. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.125 · Cited by 80 · cited 2×
“…Everolimus and temsirolimus (inhibitors of the mammalian target of rapamycin [m-TOR]) were both recently approved for treatment of renal cell cancer, causing diarrhea in up to 40% with a rate of severe diarrhea in less than 5% of patients [Hudes et al. 2007; Motzer et al. 2008; Hess et al. 2009].”
BackgroundMattison, L. K., Fourie, J., Hirao, Y., Koga, T., Desmond, R. A., King, J. R., Shimizu, T., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2020 · Cited by 76 · cited 2×
“Potentially, the simple breath test (UraBT) could be used as a screening tool [Mattison et al. 2006b].”
BackgroundMethodLenfers, B., Loeffler, T. M., Droege, C., & Hausamen, T.-U. (1999) · Annals of Oncology · doi:10.1023/a:1008390308416 · Cited by 76 · cited 1×
“In contrast, in loperamide-refractory patients the CID grade could be reduced in more than half of the patients treated with either irinotecan or 5-FU in a small case series [Lenfers et al. 1999].”
BackgroundGastrointestinal complications of oncologic therapy
Davila, M. L., & Bresalier, R. S. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1277 · Cited by 76 · cited 6×
“These include intestinal infection (e.g. Clostridium difficile), radiation, and a history of prior intestinal resection [Davila and Bresalier, 2008; Vincenzi et al. 2008].”
BackgroundInfluentialControl of irinotecan-induced diarrhea by octreotide after loperamide failure
Barbounis, V., Koumakis, G., Vassilomanolakis, M., Demiri, M., & Efremidis, A. P. (2001) · Supportive Care in Cancer · doi:10.1007/s005200000220 · Cited by 74 · cited 1×
“Octreotide is beneficial in patients with CID from fluoropyrimidines, irinotecan, and 5-FU-based chemoradiotherapy [Gebbia et al. 1993; Goumas et al. 1998; Barbounis et al. 2001].”
BackgroundChemotherapy-induced diarrhoea
Gibson, R. J., & Stringer, A. M. (2009) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32832531bb · Cited by 74 · cited 6×
“Chemotherapy-induced diarrhea CID can occur in 50 80% of patients depending on the chemotherapy regimen [Benson et al. 2004; Gibson and Stringer, 2009].”
BackgroundInfluentialInsights, Challenges, and Future Directions in Irinogenetics
Kim, T., & Innocenti, F. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318068623b · Cited by 70
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy
Gebbia, V., Carreca, I. U., Testa, A., Valenza, R., Curto, G., Cannata, G. E., Borsellino, N., Latteri, M. A., Cipolla, C., Florena, M., et al. (1993) · Anti-Cancer Drugs · doi:10.1097/00001813-199308000-00004 · Cited by 57 · cited 1×
“Octreotide is beneficial in patients with CID from fluoropyrimidines, irinotecan, and 5-FU-based chemoradiotherapy [Gebbia et al. 1993; Goumas et al. 1998; Barbounis et al. 2001].”
BackgroundSiber, G. R., Mayer, R. J., & Levin, M. J. (1980) · PubMed · Cited by 57
Mucosal injury from targeted anti-cancer therapy
Keefe, D. M. K., & Gibson, R. J. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0181-z · Cited by 54 · cited 1×
“However, there was no increase in toxicity of head and neck radiation by addition of cetuximab in a phase III trial despite a possible correlation between EGFR targeting and maturation of squamous eptithelium of the tongue and nasal cavity [Bonner et al. 2006; Keefe and Gibson, 2007].”
BackgroundAntidiarrheal agents for the management of treatment-related diarrhea in cancer patients
Ippoliti, C. M. (1998) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/55.15.1573 · Cited by 53 · cited 1×
“In addition, diarrhea can interfere with and detract from cancer treatment by causing dosing delays or reductions which may have an impact on survival [Engelking et al. 1998; Ippoliti, 1998].”
BackgroundOctreotide in the treatment of severe chemotherapy-induced diarrhea
Zidan, J., Haim, N., Beny, A., Stein, M. E., Gez, E., & Kuten, A. (2001) · Annals of Oncology · doi:10.1023/a:1008372228462 · Cited by 52 · cited 1×
“…effective than standard-dose loperamide (90 versus 15% resolution of diarrhea by day 3) [Cascinu et al. 1993], octreotide is generally reserved as a second-line treatment for patients who are refractory after 48 hours, despite a loperamide escalation, because of its high cost [Zidan et al. 2001].”
BackgroundSaccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats
Fittkau, M., Voigt, W., Holzhausen, H.-J., & Schmoll, H. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0557-8 · Cited by 52 · cited 1×
“(3) The distribution and severity of histological damage within the rat intestine after administration of irinotecan has been correlated to the luminal ß-glucuronidase activity in rodents [Takasuna et al. 1998; Fittkau et al. 2004].”
BackgroundSelf-citationCao, S., Troutt, A. B., & Rustum, Y. M. (1998) · PubMed · Cited by 51
Karthaus, M., Balló, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D. M., Kindler, M., et al. (2005) · Oncology · doi:10.1159/000086971 · Cited by 49 · cited 1×
“The published data however, only reveal a trend towards a reduction of CID from 4.2 to 1.8 days in a randomized phase II study when concomitantly loperamide was used [Karthaus et al. 2005].”
MethodInfluentialXue, H., Sawyer, M. B., Field, C. J., Dieleman, L. A., Murray, D. L., & Baracos, V. E. (2008) · Journal of Nutrition · doi:10.1093/jn/138.4.740 · Cited by 46 · cited 1×
“Preclinical data suggests that glutamine stimulates intestinal mucosa growth, displaying less gastrointestinal toxictiy in rodents treated with chemotherapy [Fox et al. 1988; Xue et al. 2008].”
BackgroundJordan, K., Kellner, O., Kegel, T., Schmoll, H., & Grothey, A. F. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.009 · Cited by 45 · cited 2×
“Irinotecan is frequently used in first- and second-line treatment of metastatic colorectal cancer [Saltz et al. 2000, 2007; Hurwitz et al. 2004; Jordan et al. 2004; Van Cutsem et al. 2009].”
Self-citationFlieger, D., Klassert, C., Hainke, S., Keller, R., Kleinschmidt, R., & Fischbach, W. (2007) · Oncology · doi:10.1159/000111083 · Cited by 45 · cited 1×
“In contrast, in a further nonrandomized study with 51 patients using levofloxacin just one patient experienced grade 3 diarrhea with no grade 4 at all [Flieger et al. 2007].”
ResultWadler, S., Haynes, H., & Wiernik, P. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.222 · Cited by 43 · cited 1×
“Guidelines for evaluation and management of patients with CID are presented in Figure 2 [Wadler et al. 1998, Benson et al. 2004].”
MethodVoigt, W., Matsui, S., Yin, M.-B., Burhans, W. C., Minderman, H., & Rustum, Y. M. (1998) · PubMed · Cited by 42
Self-citationOctreotide Acetate in the Treatment of Fluorouracil‐Induced Diarrhea
Goumas, P. D., Naxakis, S. S., Christopoulou, A. N., Chrysanthopoulos, C. J., Nikolopoulou, V., & Kalofonos, H. P. (1998) · The Oncologist · doi:10.1634/theoncologist.3-1-50 · Cited by 41 · cited 1×
“Octreotide is beneficial in patients with CID from fluoropyrimidines, irinotecan, and 5-FU-based chemoradiotherapy [Gebbia et al. 1993; Goumas et al. 1998; Barbounis et al. 2001].”
BackgroundMartenson, J. A., Halyard, M. Y., Sloan, J. A., Proulx, G. M., Miller, R. C., Deming, R. L., Dick, S. J., Johnson, H. A., Tai, T., Zhu, A. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1546 · Cited by 41 · cited 1×
“In patients receiving pelvic radiation the prophylactic treatment with 20 mg of long-acting octreotide versus placebo showed even worse tolerability regarding gastrointestinal symptoms and no change in diarrhea [Martenson et al. 2008].”
BackgroundTakasuna, K., KASAI, Y., Kitano, Y., Mori, K., KAKIHATA, K., Hirohashi, M., & Nomura, M. (1995) · Folia Pharmacologica Japonica · doi:10.1254/fpj.105.447 · Cited by 35 · cited 2×
“In summary the different mechanisms are discussed as follows: (1) Free intestinal luminal SN38 induces direct mucosal damage with water and electrolyte malabsorption and mucous hypersecretion in rats [Takasuna et al. 1995].”
BackgroundPan, C.-X., Loehrer, P. J., Seitz, D. E., Helft, P. R., Juliar, B. E., Ansari, R., Pletcher, W., Vinson, J., Liang Cheng, C., & Sweeney, C. J. (2005) · Oncology · doi:10.1159/000087302 · Cited by 35 · cited 1×
“…gliomas treated with irinotecan and celecoxib [Reardon et al. 2005], whereas in another study with the same sample size using a combination of celecoxib and glutamine with the IFL-regimen the rate was 45% for grade 3 diarrhea, which is even higher than the expected margin [Pan et al. 2005].”
ResultRosenoff, S. H. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-003-0507-z · Cited by 31 · cited 1×
“The efficacy of long-acting octreotide in the therapeutic setting has been demonstrated, as has its use in secondary prophylaxis in a small case series with doses ranging from 20 mg up to 40 mg every 4 weeks [Rosenoff, 2004a,b].”
BackgroundRosenoff, S. H., Gabrail, N. Y., Conklin, R., Hohneker, J. A., Berg, W. J., Warsi, G. M., Maloney, J. M., Benedetto, J. J., Miles, E. A., Zhu, W., et al. (2006) · PubMed · Cited by 30
Li, Y., Xu, P., Yu, B., Liu, F., Ni, X., & LI, J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04068.x · Cited by 30 · cited 1×
“Recently, a series with 44 patients showed a significant reduction in diarrhea with prophylactic use of intravenous glutamine — any influence on survival was not reported [Li et al. 2009].”
BackgroundCascinu, S., Bichisao, E., Amadori, D., Silingardi, V., Giordani, P., Sansoni, E., Luppi, G., Catalano, V., Agostinelli, R., & Catalano, G. (2000) · Supportive Care in Cancer · doi:10.1007/s005209900085 · Cited by 29 · cited 1×
“These recommendations by the consensus conference mentioned above reflect the risk of life-threatening complications and the reduced activity of loperamide in cases of severe diarrhea [Cascinu et al. 2000].”
BackgroundPredictive factors for chemotherapy-related toxic effects in patients with colorectal cancer
Vincenzi, B., Schiavon, G., Pantano, F., Santini, D., & Tonini, G. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1137 · Cited by 29 · cited 6×
“These include intestinal infection (e.g. Clostridium difficile), radiation, and a history of prior intestinal resection [Davila and Bresalier, 2008; Vincenzi et al. 2008].”
BackgroundInfluentialRosenoff, S. H. (2004) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2004.00511.x · Cited by 28 · cited 1×
“The efficacy of long-acting octreotide in the therapeutic setting has been demonstrated, as has its use in secondary prophylaxis in a small case series with doses ranging from 20 mg up to 40 mg every 4 weeks [Rosenoff, 2004a,b].”
BackgroundCancer-related diarrhea: a neglected cause of cancer-related symptom distress.
Engelking, C., Rutledge, D. N., Ippoliti, C. M., Neumann, J., & Cm, H. (1998) · PubMed · Cited by 23
Activated charcoal to prevent irinotecan‐induced diarrhea in children
Gallegos‐Castorena, S., Félix, G., & Luis, J. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21491 · Cited by 23
Wasserman, E., Hidalgo, M. M., Hornedo, J., & Cortés-Funes, H. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700965 · Cited by 19
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea
Schmittel, A. H., Jahnke, K., Thiel, E., & Keilholz, U. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh310 · Cited by 17 · cited 2×
“Despite promising results in a small series for secondary prophylaxis [Schmittel et al. 2004], a recent randomized phase II study displayed only a nonsignificant reduction of grade 3 diarrhea from 32.4 to 17.9% [De Jong et al. 2006].”
ResultInfluentialDoes Celecoxib Have a Role in the Treatment of Patients with Colorectal Cancer?
Fakih, M., & Rustum, Y. M. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.002 · Cited by 12 · cited 1×
“In a recent review, no improvement with the usage of celecoxib in reducing CID was observed in the analyzed studies [Fakih and Rustum, 2009].”
BackgroundTyrosine kinase inhibitors and gut toxicity: a new era in supportive care
Keefe, D. M. K., & Anthony, L. B. (2008) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282f5273f · Cited by 12 · cited 1×
“Regarding the increasing utilization of targeted therapies further research to gain the ability to prevent diarrhea is urgently warranted [Keefe and Anthony, 2008].”
BackgroundZachariah, B., James, J., Gwede, C. K., Ajani, J. A., Chin, L. J., Donath, D., Kane, B. L., Rotman, M., & Berk, L. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4032 · Cited by 4 · cited 1×
“…results of a study presented by Zacchariah and colleagues at ASCO 2007 in the primary prophylaxis of diarrhea in 215 rectal cancer patients receiving 5-FU based chemoradiation was negative, revealing no difference between placebo and 30 mg of long-acting octreotide [Zachariah et al. 2007].”
Result
Research works printed but not linked: 9
- Cao, S., 1998, Cancer Res, 58, 1695
- Dupont, H.L., 1997, Am J Gastroenterol, 92, 1962
- Engelking, C., 1998, Oncol Nurs Forum, 25, 859
- Kehrer, D.F., 2001, Clin Cancer Res, 7, 1136
- Rosenoff, S.H., 2006, J Support Oncol, 4, 289
- Siber, G.R., 1980, Cancer Res, 40, 3430
- Stringer, A.M., 2007, Experimental Biology and Medicine, 232, 96
- Trifan, O.C., 2002, Cancer Res, 62, 5778
- Voigt, W., 1998, Anticancer Res, 18, 3499
Cited by
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
“SN-38G’s secretion into the bile and subsequent deconjugation by beta-glucuronidase produced by the intestinal flora is strongly implicated in the enterohepatic recirculation of SN-38 and the delayed severe diarrhea observed with irinotecan [52].”
BackgroundThe emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
“com concentrations of SN-38G in the serum might explain this difference, since the re-circulation of SN-38G is suspected to be responsible for late diarrhea in IRI therapy [117, 118].”
Background
Metadata
- Authors
- Stein, A., Voigt, W., & Jordan, K.
- Affiliations
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Stein, Alexander
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2009-12-04
- Volume
- 2
- Issue
- 1
- Pages
- 51-63
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- PMC
- PMC3126005
- OpenAlex
- W2125060052
- Cited by
- 431
- References
- 95
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 30 · 2023: 39 · 2022: 37 · 2021: 35 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 28 · 2016: 14 · 2015: 22 · 2014: 26 · 2013: 11 · 2012: 5
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Medical Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- chemotherapy-induced diarrhea, pathophysiology, 5-fluorouracil, irinotecan, fluoropyrimidine, loperamide, octreotide, prophylaxis, budesonide, probiotics, activated carbon, antibiotic prophylaxis, UGT1A1 polymorphism, dihydropyrimidine dehydrogenase deficiency, predictive factors, chemotherapy side effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.